# Yayoi Tada

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/yayoi-tada/

## Facts

| Field | Value |
| --- | --- |
| Citations | 6,433 |
| Field | Psoriasis: Treatment and Pathogenesis |
| h-index | 40 |
| i10-index | 129 |
| Last Known Institution | Teikyo University Hospital |
| OpenAlex ID | https://openalex.org/A5030954224 |
| ORCID iD | 0000-0003-3743-135X |
| Works | 313 |

## Researcher papers

- [Thymus and activation-regulated chemokine in atopic dermatitis: Serum thymus and activation-regulated chemokine level is closely related with disease activity](https://scholariq.org/papers/thymus-and-activation-regulated-chemokine-in-atopic-dermatitis-serum-thymus-and/)
- [Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review](https://scholariq.org/papers/efficacy-and-safety-of-biologics-for-psoriasis-and-psoriatic-arthritis-and-their/)
- [Interleukin-12 p40 gene (IL12B) 3′-untranslated region polymorphism is associated with susceptibility to atopic dermatitis and psoriasis vulgaris](https://scholariq.org/papers/interleukin-12-p40-gene-il12b-3-untranslated-region-polymorphism-is-associated/)
- [Dendritic Cells and Macrophages in the Pathogenesis of Psoriasis](https://scholariq.org/papers/dendritic-cells-and-macrophages-in-the-pathogenesis-of-psoriasis/)
- [Adiponectin regulates psoriasiform skin inflammation by suppressing IL-17 production from γδ-T cells](https://scholariq.org/papers/adiponectin-regulates-psoriasiform-skin-inflammation-by-suppressing-il-17/)
- [IL‐18 enhances IFN‐γ‐induced production of CXCL9, CXCL10, and CXCL11 in human keratinocytes](https://scholariq.org/papers/il-18-enhances-ifn-induced-production-of-cxcl9-cxcl10-and-cxcl11-in-human/)
- [Increased serum cutaneous T cell-attracting chemokine (CCL27) levels in patients with atopic dermatitis and psoriasis vulgaris](https://scholariq.org/papers/increased-serum-cutaneous-t-cell-attracting-chemokine-ccl27-levels-in-patients/)
- [Safety of biologics in psoriasis](https://scholariq.org/papers/safety-of-biologics-in-psoriasis/)
- [A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial*](https://scholariq.org/papers/a-head-to-head-comparison-of-ixekizumab-vs-guselkumab-in-patients-with-moderate/)
- [Association of the numbers of CD163+ cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma](https://scholariq.org/papers/association-of-the-numbers-of-cd163-cells-in-lesional-skin-and-serum-levels-of/)
- [Impact of 1‐year treatment with dupilumab on work productivity in Japanese patients with atopic dermatitis](https://scholariq.org/papers/impact-of-1-year-treatment-with-dupilumab-on-work-productivity-in-japanese/)

## Researcher topics

- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)
- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)
- [Autoimmune Bullous Skin Diseases](https://scholariq.org/topics/autoimmune-bullous-skin-diseases/)
- [Urticaria and Related Conditions](https://scholariq.org/topics/urticaria-and-related-conditions/)
- [Spondyloarthritis Studies and Treatments](https://scholariq.org/topics/spondyloarthritis-studies-and-treatments/)

## Researcher university

- [Teikyo University Hospital](https://scholariq.org/institutions/teikyo-university-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.